Makers of Wegovy and Zepbound cut prices for those without insurance
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance.
obesity drugs
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 — The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Novo Nordisk, the Danish company behind Wegovy…
Naturally occurring molecule rivals Ozempic in weight loss, sidesteps side effects
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as Ozempic—in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of the drug’s side effects, such as nausea, constipation and significant loss of muscle mass.
Novo Nordisk cuts Wegovy prices after similar move by Zepbound maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance
Taking semaglutide before bariatric surgery does not improve weight loss or safety, study finds
Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight-loss surgery, suggesting that a surgery-first strategy could lead to better outcomes.
FDA Approves Generic Liraglutide to Address GLP-1 Drug Shortage
The US Food and Drug Administration (FDA) recently approved liraglutide to treat type 2 diabetes in combination with diet and exercise, which makes it the first generic version of Victoza and the second glucagon-like peptide-1 (GLP-1) receptor agonist authorized as a generic drug.
